Gevo (NASDAQ:GEVO) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday, Analyst Ratings.Net reports. The firm currently has a $1.50 price objective on the stock.Zacks‘s target price suggests a potential upside of 31.58% from the stock’s previous close. Gevo, Inc. (NASDAQ:GEVO), shares after opening at $1.03 moved to $1.05 on last trade day and at the end of the day closed at $0.844. Company price to sales ratio in past twelve months was calculated as 6.76 and price to cash ratio as 2.25. Gevo, Inc. (NASDAQ:GEVO), showed a negative weekly performance of 28.46%.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares are surging higher 25% on volume of 200 following the firm declared positive results in a clinical trial of type 1 diabetes drug LX4211. The trial discovered that the drug effectively lowered insulin use and enhanced glycemic control in patients with badly controlled diabetes. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), shares sustain 0.00% in last trading session and ended the day on $1.55. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), return on equity ratio is recorded as -51.30% and its return on assets is -33.50%. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), yearly performance is -28.57%.
Neonode, Inc (NASDAQ:NEON) posted a video demonstrating Apple’s (AAPL) using its technology, and announced that Hewlett-Packard (HPQ) will use its technology in new printers. Neonode, Inc (NASDAQ:NEON), shares moved up 0.83% in last trading session and was closed at $4.84, while trading in range of $4.49 – $5.22. Neonode, Inc (NASDAQ:NEON), year to date (YTD) performance is -23.42%.
On April 9, 2014, VimpelCom Ltd (ADR) (NASDAQ:VIP) announced that it has now successfully completed its new RCF-revolving-credit facility of upto USD 1.8B for VimpelCom Amsterdam B.V. This RCF has a 3- year tenure and its will replace the existing US$500M RCF that was signed in 2011. Currently 11 different banks have committed to this RCF in an aggregate-amount of US$1.65 billion. This RCF contains the option to increase this amount of this facility by upto US$150M within 6 months from date of signing. VimpelCom Ltd (ADR) (NASDAQ:VIP) also announced that it has now successfully completed the new term-facility of US$0.5B for VIP Amsterdam. VimpelCom Ltd (ADR) (NASDAQ:VIP), weekly performance is -6.02%. On last trading day company shares ended up $7.96. VimpelCom Ltd (ADR) (NASDAQ:VIP), distance from 50-day simple moving average (SMA50) is -14.32%. Analysts mean target Price for the company is $11.16.